TIDMTTM

RNS Number : 6174D

Almea 2 Segregated Portfolio Co.

20 February 2020

Ap27

   FORM   38.5(b) 
   IRISH  TAKEOVER   PANEL 
   DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH  TAKEOVER   PANEL ACT,  1997,  TAKEOVER  RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED

INTERMEDIARY   STATUS  BUT NOT DEALING IN A  CLIENT-SERVING   CAPACITY 
   1.          KEY   INFORMATION 
 
Name of exempt principal    Almea 2 Segregated Portfolio 
 trader                      Company 
Company dealt in            AbbVie Inc. 
                            ============================ 
Class of relevant security  Common stock 
 to which the dealings 
 being disclosed relate 
 (Note 1) 
                            ============================ 
Date of dealing             19 February 2020 
                            ============================ 
 
   2.          INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant

security   dealt   in   (Note   2) 
 
                                          Long                 Short 
                             Number        (%)      Number       (%) 
                             ==========   =======  ===========  ====== 
(1) Relevant securities                              9,005 0.00% 
                                                   =================== 
(2) Derivatives (other 
 than options) 
                             ====================  =================== 
(3) Options and agreements 
 to purchase/sell 
                             ====================  =================== 
Total                                               9,005 0.00% 
                                                   ===================

(b) Interests and short positions in relevant securities of the company, other than the class dealt

in   (Note   2) 
 
Class of relevant security:               Long                Short 
                             Number        (%)     Number         (%) 
                             =========    ======  ===========    ====== 
(1) Relevant securities 
                             ===================  ===================== 
(2) Derivatives (other 
 than options) 
                             ===================  ===================== 
(3) Options and agreements 
 to purchase/sell 
                             ===================  ===================== 
Total 
                             ===================  =====================

Ap28

   3.       DEALINGS  (Note   3) 
   (a)      Purchases and sales 
 
 Purchase/sale         Number of relevant securities        Price per unit 
                                                               (Note 4) 
                                                                (USD) 
     Buy                       2,644                        94.1055 
                                1,129                        94.3595 
                ====================================  ==================== 
 
   (b)      Derivatives transactions (other than options transactions) 
 
  Product    Nature of transaction   Number of relevant   Price per 
   name,            (Note 5)             securities          unit 
  e.g. CFD                                (Note 6)         (Note 4) 
 
 
   (c)      Options transactions in respect of existing relevant securities 
   (i)       Writing,   selling, purchasing or varying 
 
  Product       Writing,       Number of      Exercise        Type,       Expiry          Option 
    name,       selling,       securities       price     e.g. American,   date     money paid/received 
  e.g. call    purchasing,      to which                     European                    per unit 
   option        varying       the option                      etc.                      (Note 4) 
                  etc.        relates (Note 
                                   7) 
 
 
   (ii)      Exercising 
 
 Product name,             Number of securities       Exercise price 
  e.g. call option                                     per unit (Note 
                                                       4)

(d) Other dealings (including transactions in respect of new securities) (Note 3)

 
 Nature of transaction         Details       Price per unit 
  (Note 7)                                    (if applicable) 
                                              (Note 4)

Ap29

   4.       OTHER  INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other

person   relating   to   the   voting   rights   of   any   relevant   securities

under any option referred to on this form or relating to the voting rights or future

acquisition or disposal of any relevant securities to which any derivative referred to on this form is

  referenced.   If   none,   this   should   be   stated. 
   Is a Supplemental Form 38.5(b) attached?  (Note   8)                     NO 
 
Date of disclosure           20 February 2020 
Contact name                 Alwyn Basch 
                             ============================= 
Telephone number             020 7742 7407 
                             ============================= 
Name of offeree/offeror      Allergan plc 
 with which connected 
                             ============================= 
Nature of connection (Note   Financial Advisor to Allergan 
 9)                           plc 
                             =============================

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ISEBGGDDUXDDGGG

(END) Dow Jones Newswires

February 20, 2020 05:37 ET (10:37 GMT)